Fig. 4
From: Targeting CRAF kinase in anti-cancer therapy: progress and opportunities
Binding mode of type I & II RAF inhibitors. a DFG-in conformation for PDB 3OG7 (crystalized with vemurafenib, specifically targets BRAFV600E via selectively binding to the "active" DFG-in and αC-helix-out conformation of the ATP binding site); b DFG-out conformation for PDB 1UWJ (crystalized with sorafenib, "inactive" DFG-out and αC-helix-in conformation of the ATP binding site). This figure has been adapted from Wang, L. et al. [21]